There is no other company that has been under constant suppression from the dark forces and yet can still survive on OTC for such a long time. You should know this better since you are most likely Fraudstein's minion.
Here is something Fraudstein would never teach you. He is not equipped to.
See this paper. Timothy Cloughesy found that use pd1 inhibitor as neoadjuvant rather than using it as adjuvant can double OS for rGBM patients.
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Here is the figure on t-cell infiltration. See the number of green dots which are the CD8 t-cells.
Now take a look at the t-cell infiltration figure from the p3 trial. There are more CD8 t-cell infiltration into tumor site. Moreover, there are CD4 t-cell infiltration and CD4 plays crucial role in immune memory and it can only be triggered by antigen presenting cells.
Here comes the exciting part. See the figure on t-cell infiltration from the combo trial. The red dots are the t-cells. There are a lot more. Now you should know why tumor shrinkage will be adopted as an outcome measure for future trial. Remind yourself again how long it took for the amazing increase in the number of t-cells.
Market Data 
Markets 
